Publications by authors named "Johan F K F Ilvemark"
Background And Aims: Reliable and easily accessible objective markers of disease activity to predict long-term treatment outcomes in severe ulcerative colitis (UC) are missing. We aimed to investigate if intestinal ultrasound (IUS) might predict long-term outcomes in hospitalized patients with severe UC treated with intravenous corticosteroids.
Methods: Hospitalized patients with severe UC and IUS inflammation (bowel wall thickness (BWT)>3.
Background And Aims: To demonstrate that administration of 7500 Trichuris suis ova [TSO] every second week over 24 weeks would reduce the intestinal inflammation in moderate ulcerative colitis.
Methods: A single-centre, randomised, double-blinded, placebo-controlled, phase 2b clinical trial of 7500 Trichuris suis ova every 2 weeks for 24 weeks compared with placebo in moderate activity of ulcerative colitis [Mayo score 6-10] were performed. Primary outcome: clinical remission; secondary outcomes: clinical response at 24 weeks, complete corticosteroid-free clinical remission, endoscopic remission, symptomatic remission at 12 and 24 weeks, and partial Mayo score over time.
Article Synopsis
- A study was conducted to evaluate how prednisolone affects clinical outcomes and safety in ulcerative colitis patients treated with infliximab, with a focus on corticosteroid-free clinical remission (CFCR).
- Among the 147 patients reviewed, there was no overall association between prednisolone use and CFCR at weeks 14 or 52, but standard tapering of prednisolone showed better results compared to faster tapering regimens.
- Despite no impact on infliximab levels, higher infection rates were noted in patients taking prednisolone, especially in those with greater disease severity, suggesting that corticosteroid therapy may benefit certain patients.
Ulcerative colitis (UC) is part of the inflammatory bowels diseases, and moderate to severe UC patients can be treated with anti-tumour necrosis α monoclonal antibodies, including infliximab (IFX). Even though treatment of UC patients by IFX has been in place for over a decade, many gaps in modelling of IFX PK in this population remain. This is even more true for acute severe UC (ASUC) patients for which early prediction of IFX pharmacokinetic (PK) could highly improve treatment outcome.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess whether changes in intestinal ultrasound after 48 hours of corticosteroid treatment could predict recovery in hospitalized patients with severe ulcerative colitis.
- A multicenter observational study involving 69 patients was conducted, measuring bowel wall thickness before treatment, after 48 hours, and at 6 days, determining treatment response based on specific scores.
- Results showed that a greater than 20% reduction in bowel thickness after 48 hours was strongly linked to treatment response, indicating its potential as an early indicator for guiding further therapy.
Background And Aims: No consensus exists on defining intestinal ultrasound response, transmural healing, or transmural remission in inflammatory bowel disease, nor clear guidance for optimal timing of assessment during treatment. This systematic review and expert consensus study aimed to define such recommendations, along with key parameters included in response reporting.
Methods: Electronic databases were searched from inception to July 26, 2021, using pre-defined terms.
Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease.
United European Gastroenterol J
February 2021
Background: Infliximab therapy during pregnancy in inflammatory bowel disease is challenged by a dilemma between maintaining adequate maternal disease control while minimizing fetal infliximab exposure. We investigated the effects of pregnancy on infliximab pharmacokinetics.
Methods: The study population comprised 23 retrospectively identified pregnancies.